BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 14738451)

  • 1. Stimulation of innate immunity by susceptible and multidrug-resistant Pseudomonas aeruginosa: an in vitro and in vivo study.
    Giamarellos-Bourboulis EJ; Plachouras D; Tzivra A; Kousoulas V; Bolanos N; Raftogiannis M; Galani I; Dontas I; Dionyssiou-Asteriou A; Giamarellou H
    Clin Exp Immunol; 2004 Feb; 135(2):240-6. PubMed ID: 14738451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of multidrug resistance on experimental empyema by Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ; Tzepi I; Tsovolou I; Spyridaki A; Tsaganos T; Vaki I; Kotsaki A; Polychronopoulos V
    Respiration; 2011; 82(1):46-53. PubMed ID: 21525725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental sepsis using Pseudomonas aeruginosa: the significance of multi-drug resistance.
    Giamarellos-Bourboulis EJ; Koussoulas V; Panagou C; Adamis T; Baziaka F; Skiadas I; Perrea D; Dionyssiou-Asteriou A; Giamarellou H
    Int J Antimicrob Agents; 2004 Oct; 24(4):357-61. PubMed ID: 15380261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early cutaneous alterations in experimental sepsis by Pseudomonas aeruginosa.
    Petropoulou H; Giamarellos-Bourboulis EJ; Kavatzas N; Stratigos A; Mouktaroudi M; Adamis T; Baziaka F; Katsambas AD; Stavrianeas NG
    Dermatology; 2004; 209(2):111-6. PubMed ID: 15316164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiopoietin-2 enhances survival in experimental sepsis induced by multidrug-resistant Pseudomonas aeruginosa.
    Tzepi IM; Giamarellos-Bourboulis EJ; Carrer DP; Tsaganos T; Claus RA; Vaki I; Pelekanou A; Kotsaki A; Tziortzioti V; Topouzis S; Bauer M; Papapetropoulos A
    J Pharmacol Exp Ther; 2012 Nov; 343(2):278-87. PubMed ID: 22859861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-treatment with probiotics prolongs survival after experimental infection by multidrug-resistant Pseudomonas aeruginosa in rodents: an effect on sepsis-induced immunosuppression.
    Machairas N; Pistiki A; Droggiti DI; Georgitsi M; Pelekanos N; Damoraki G; Kouraklis G; Giamarellos-Bourboulis EJ
    Int J Antimicrob Agents; 2015 Apr; 45(4):376-84. PubMed ID: 25601531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. n-6 polyunsaturated fatty acids enhance the activities of ceftazidime and amikacin in experimental sepsis caused by multidrug-resistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ; Mouktaroudi M; Adamis T; Koussoulas V; Baziaka F; Perrea D; Karayannacos PE; Giamarellou H
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4713-7. PubMed ID: 15561848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions of Klebsiella pneumoniae with the innate immune system vary in relation to clone and resistance phenotype.
    Pantelidou IM; Galani I; Georgitsi M; Daikos GL; Giamarellos-Bourboulis EJ
    Antimicrob Agents Chemother; 2015 Nov; 59(11):7036-43. PubMed ID: 26349819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ; Adamis T; Laoutaris G; Sabracos L; Koussoulas V; Mouktaroudi M; Perrea D; Karayannacos PE; Giamarellou H
    Antimicrob Agents Chemother; 2004 Jan; 48(1):93-9. PubMed ID: 14693524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ; Antonopoulou A; Raftogiannis M; Koutoukas P; Tsaganos T; Tziortzioti V; Panagou C; Adamis T; Giamarellou H
    BMC Infect Dis; 2006 Feb; 6():31. PubMed ID: 16504031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the acute inflammatory response to Pseudomonas aeruginosa infection: differences between susceptible and multidrug-resistant strains in a mouse peritonitis model.
    Gómez-Zorrilla S; Calatayud L; Juan C; Cabot G; Tubau F; Oliver A; Dominguez MA; Ariza J; Peña C
    Int J Antimicrob Agents; 2017 Feb; 49(2):198-203. PubMed ID: 27939091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional profiles of pulmonary innate immune responses to isogenic antibiotic-susceptible and multidrug-resistant Pseudomonas aeruginosa.
    Tam VH; Pérez C; Ledesma KR; Lewis RE
    Microbiol Immunol; 2018 Apr; 62(4):291-294. PubMed ID: 29418013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulatory intervention in sepsis by multidrug-resistant Pseudomonas aeruginosa with thalidomide: an experimental study.
    Giamarellos-Bourboulis EJ; Bolanos N; Laoutaris G; Papadakis V; Koussoulas V; Perrea D; Karayannacos PE; Giamarellou H
    BMC Infect Dis; 2005 Jun; 5():51. PubMed ID: 15978135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute Inflammatory Response of Patients with Pseudomonas aeruginosa Infections: A Prospective Study.
    Gómez-Zorrilla S; Morandeira F; Castro MJ; Tubau F; Periche E; Cañizares R; Dominguez MA; Ariza J; Peña C
    Microb Drug Resist; 2017 Jun; 23(4):523-530. PubMed ID: 27754817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oleuropein: a novel immunomodulator conferring prolonged survival in experimental sepsis by Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ; Geladopoulos T; Chrisofos M; Koutoukas P; Vassiliadis J; Alexandrou I; Tsaganos T; Sabracos L; Karagianni V; Pelekanou E; Tzepi I; Kranidioti H; Koussoulas V; Giamarellou H
    Shock; 2006 Oct; 26(4):410-6. PubMed ID: 16980890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of multidrug resistance on the pathogenicity of Escherichia coli: an experimental study.
    Bristianou M; Panagou C; Adamis T; Raftogiannis M; Antonopoulou A; Chrisofos M; Galani I; Kanellakopoulou K; Tsaganos T; Giamarellos-Bourboulis EJ
    Int J Antimicrob Agents; 2008 Mar; 31(3):216-23. PubMed ID: 18248963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The significance of oxidant/antioxidant balance for the pathogenesis of experimental sepsis by multidrug-resistant Pseudomonas aeruginosa.
    Koussoulas V; Giamarellos-Bourboulis EJ; Adamis T; Mouktaroudi M; Sabracos L; Perrea D; Giamarellou H; Dionyssiou-Asteriou A
    Prostaglandins Leukot Essent Fatty Acids; 2005 Jan; 72(1):41-7. PubMed ID: 15589398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulatory effect of three-day continuous administration of clarithromycin for experimental sepsis due to multidrug-resistant Pseudomonas aeruginosa.
    Baziaka F; Giamarellos-Bourboulis EJ; Raftogiannis M; Adamis T; Tziortzioti V; Sabracos L; Chrisofos M; Koutoukas P; Giamarellou H; Douzinas EE
    J Chemother; 2008 Feb; 20(1):63-8. PubMed ID: 18343746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of clinical extensively drug-resistant Pseudomonas aeruginosa in the Hunan province of China.
    Li J; Zou M; Dou Q; Hu Y; Wang H; Yan Q; Liu WE
    Ann Clin Microbiol Antimicrob; 2016 May; 15(1):35. PubMed ID: 27215335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
    Hu YF; Liu CP; Wang NY; Shih SC
    BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.